Efficacy of GONB in Patients of Migraine

Analgesic Efficacy of Ultrasound-guided Greater Occipital Nerve Block in Patients of Chronic Migraine

The study was carried to determine the analgesic efficacy of greater occipital nerve block in patients of migraine. It was a randomised controlled which took place from april 2022 - october 2022. Fifty patients suffering from migraine were included in the study. Patients in Group G were given greater occipital nerve block (GONB) with lignocaine and dexamethasone under ultrasound guidance while those in Group S were given saline 0.9% as placebo. Pain score using Numeric Rating Scale and number of headache days was assessed at four,eight and twelve weeks after the procedure as a primary outcome. Total headache days were recorded as a secondary outcome.

Greater occipital nerve block (GONB) under ultrasound guidance with lidocaine and dexamethasone on the side of headache

Greater occipital nerve block (GONB) under ultrasound guidance on the side of headache with 0.9% Saline (Placebo)

Change in Pain score assessed on Numeric Rating Scale (NRS) which ranges from 0 to 10. 0 is no pain and 10 is maximum pain.

Inclusion Criteria: Patients between 18 to 60 years diagnosed case of migraine Exclusion Criteria: Patients with known allergies to local anaesthetics pregnancy history of cranial or cervical surgery head injury headaches secondary to medication overuse patients with uncontrolled systemic disease like blood pressure, diabetes mellitus hypo or hyperthyroidism patient who had already received GONB or botulinum toxin type A therapy within last 6 months major psychiatric disorder history of chronic pain syndromes